GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Tax Expense

Conduit Pharmaceuticals (Conduit Pharmaceuticals) Tax Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Tax Expense?

Conduit Pharmaceuticals's tax expense for the months ended in Mar. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Conduit Pharmaceuticals Tax Expense Historical Data

The historical data trend for Conduit Pharmaceuticals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Tax Expense Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Tax Expense
- - -

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial - - - - -

Conduit Pharmaceuticals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals  (NAS:CDT) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Conduit Pharmaceuticals Tax Expense Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Executives
Intelmed Llc other: See Responses 11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay director, officer: Chief Executive Officer 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Andrew Regan director, 10 percent owner LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc. 10 percent owner, other: See Responses 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd. 10 percent owner, other: See Responses WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh director 38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc 10 percent owner 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg director 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc 10 percent owner 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley director 4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv officer: Chief Accounting Officer 2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron director, officer: CEO, President, and Chairman 16433 BRONCO LANE, POWAY CA 92064